Unofficial Proposal · Not the official Anterogen website
ANTEROGENFOR HUMAN TISSUE REGENERATION
KORCNContact

03 PIPELINE

Pipeline

Anterogen advances approved products and development programs according to their target indications and development stages.

Public Projects5

The most advanced development stage disclosed is indicated for each project. Please check the detailed text if stages vary by country.

01 · Approved Product

ALLOSTEM SHEET

ALLO-ASC-DEB · ALLO-ASC-EBEpidermolysis Bullosa
  1. Preclinical✓
  2. Phase 1✓
  3. Phase 2✓
  4. Phase 3✓
  5. ApprovedCurrent
Japan · USMarketing Approval in Japan · Phase 2 in USAllogeneic MSC Sheet

Received marketing approval from Japan MHLW in April 2026, currently in Phase 2 clinical trials in the US.

As of · Japan Approved 2026.04.03 · US Stage 2026.03.31
02 · Clinical Development

ALLO-ASC-DFU

Diabetic Foot Ulcer
  1. Preclinical✓
  2. Phase 1✓
  3. Phase 2✓
  4. Phase 3Current
  5. Approved·
Korea · USAnalysis after Phase 3 in Korea · Phase 2 in USAllogeneic MSC

Analysis ongoing after completion of Phase 3 in Korea. Currently in Phase 2 clinical trials in the US.

As of · 2026.03.31
03 · Clinical Development

ALLO-ASC-CD

Crohn's Disease
  1. Preclinical✓
  2. Phase 1Current
  3. Phase 2·
  4. Phase 3·
  5. Approved·
KoreaPhase 1Allogeneic MSC

Pipeline currently under development in domestic Phase 1 clinical trials for Crohn's disease.

As of · 2026.03.31
04 · Clinical Development

ANT-301

ALLO-ASC-OAOsteoarthritis
  1. Preclinical✓
  2. Phase 1Current
  3. Phase 2·
  4. Phase 3·
  5. Approved·
Korea · USEvaluation after Phase 1 in Korea · IND Review in USStem Cell Regenerative Therapy

Evaluation ongoing after completion of Phase 1 dosing in Korea. US IND review is currently in progress.

As of · 2026.03.31
05 · Preclinical Development

ANT-501

POM-L-BHDUHerpes Zoster
  1. PreclinicalCurrent
  2. Phase 1·
  3. Phase 2·
  4. Phase 3·
  5. Approved·
Korea · USPreclinicalSmall Molecule Nucleoside Prodrug

An oral antiviral new drug candidate being researched targeting the Varicella-Zoster Virus.

As of · 2026.03.31